Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 3:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 5,852 matching trials from the live ClinicalTrials.gov search.
Filters: "gene therapy" Clear all
Completed Phase 1 Interventional

Study of a New Anti-HIV Drug, T-20, in HIV-Infected Children

NCT00001118
View directory record Official record
Conditions
HIV Infections
Interventions
Enfuvirtide
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 12 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
24
States / cities
La Jolla, California • Long Beach, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 16, 2026, 3:23 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Vitamin D Supplementation in RNA-seq Profiles of Single-core Prostate Samples, Among Veterans

NCT04621500
View directory record Official record
Conditions
Prostate Cancer, Vitamin D Deficiency, Stress Reaction
Interventions
cholecalciferol, Standard of Care Prostate Biopsy - collection of 13th core for RNA-seq, Standard of Care Prostate Biopsies at baseline and after one year vitamin D3 supplementation, Allostatic Load
Drug · Procedure · Diagnostic Test
Lead sponsor
Medical University of South Carolina
Other
Eligibility
50 Years to 75 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 4, 2025 · Synced Oct 16, 2026, 3:23 PM EDT
Completed No phase listed Observational

Hormonal Changes in Early Pregnancy

NCT00340028
View directory record Official record
Conditions
Pregnancy
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
25 Years to 35 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 1, 2025 · Synced Oct 16, 2026, 3:23 PM EDT
Completed Phase 1 Interventional Results available

Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma

NCT01593696
View directory record Official record
Conditions
ALL, B Cell Lymphoma, Leukemia, Large Cell Lymphoma, Non-Hodgkin Lymphoma
Interventions
Anti-Cluster of Differentiation (CD)19-Chimeric antigen receptor (CAR)
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 30 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2020 · Synced Oct 16, 2026, 3:23 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients

NCT03814746
View directory record Official record
Conditions
Sickle Cell Disease (SCD)
Interventions
Crizanlizumab (SEG101), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 100 Years
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
5
States / cities
Atlanta, Georgia • Boston, Massachusetts • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 16, 2026, 3:23 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Studying Health Outcomes After Treatment in Patients With Retinoblastoma

NCT03932786
View directory record Official record
Conditions
Retinoblastoma, Cancer Survivor, Biological Sibling, Intraocular Retinoblastoma, Unilateral Retinoblastoma
Interventions
Biospecimen collection, Vision assessment, Questionnaire administration, Quality of life assessment, Laboratory Biomarker Analysis
Procedure · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
Not listed
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2031
U.S. locations
10
States / cities
Chicago, Illinois • Minneapolis, Minnesota • St Louis, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2025 · Synced Oct 16, 2026, 3:23 PM EDT
Completed No phase listed Observational Results available

Dietary Supplement With and Without a Probiotic and/or Antibiotic

NCT05141903
View directory record Official record
Conditions
Healthy Adults
Interventions
Antibiotic, HMO Concentrate, Probiotic, Food Supplement
Dietary Supplement
Lead sponsor
Prolacta Bioscience
Industry
Eligibility
18 Years to 75 Years
Enrollment
92 participants
Timeline
2021 – 2022
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Oct 16, 2026, 3:23 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Phase 1/Phase 2 Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Intravenous Administration of SAR444836 in Adult Participants With Phenylketonuria

NCT05972629
View directory record Official record
Conditions
Phenylketonuria
Interventions
SAR444836
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
7
States / cities
San Francisco, California • Aurora, Colorado • Gainesville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Oct 16, 2026, 3:23 PM EDT
Recruiting Not applicable Interventional

5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy

NCT04288427
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Prostate Hyperplasia, Prostate Disease, Prostate Hypertrophy, Prostate Pain, Lower Urinary Tract Symptoms, Urinary Obstruction, Urinary Tract Disease
Interventions
Finasteride
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
50 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Oct 16, 2026, 3:23 PM EDT
Terminated No phase listed Observational

ChemoFx® PRO - A Post-Market Data Collection Study

NCT00669422
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Uterine Neoplasms, Endometrial Cancer, Vaginal Cancer, Vulvar Cancer, Cervical Cancer
Interventions
Not listed
Lead sponsor
Precision Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
2,756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
67
States / cities
Birmingham, Alabama • Mobile, Alabama • San Francisco, California + 59 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2012 · Synced Oct 16, 2026, 3:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Temporal Genomics Mechanisms Underlying Disease and Aging

NCT03637751
View directory record Official record
Conditions
Gene Expression in Response to Acute Stress
Interventions
Behavioral, Control condition
Behavioral
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 25 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Oct 16, 2026, 3:23 PM EDT
Completed Phase 4 Interventional Results available

CGRP, Estrogen, Cortisol, VIP, α-Amylase, PGE2, PGI2 and ß-Endorphin Levels in Menstrual Migraine Before and After Treximet

NCT01329562
View directory record Official record
Conditions
Menstrual Migraine
Interventions
Treximet, Placebo
Drug
Lead sponsor
Cady, Roger, M.D.
Individual
Eligibility
18 Years to 45 Years · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Springfield, Missouri • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 9, 2014 · Synced Oct 16, 2026, 3:23 PM EDT
Recruiting No phase listed Observational

Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms

NCT01005654
View directory record Official record
Conditions
Endocrine Tumors, Thyroid Neoplasms, Parathyroid Neoplasms, Adrenal Neoplasm, Neuroblastoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
4 Years and older
Enrollment
2,415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 16, 2026, 3:23 PM EDT
Completed Phase 1 Interventional

Gene-Modified White Blood Cells Followed By Interleukin-2 and Vaccine Therapy in Treating Patients With Metastatic Melanoma

NCT00085462
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
aldesleukin, filgrastim, gp100-fowlpox vaccine, therapeutic autologous lymphocytes, therapeutic tumor infiltrating lymphocytes, cyclophosphamide, fludarabine phosphate
Biological · Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 22, 2012 · Synced Oct 16, 2026, 3:23 PM EDT
Completed Not applicable Interventional

Examining Genetic Differences Among People With 21-Hydroxylase Deficiency

NCT00542841
View directory record Official record
Conditions
21-hydroxylase Deficiency
Interventions
Hydrocortisone withdrawal
Procedure
Lead sponsor
Maria I. New
Other
Eligibility
18 Years to 50 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
New York, New York • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Oct 16, 2026, 3:23 PM EDT
Completed No phase listed Observational

Studying Tumor Tissue Samples From Patients With Soft Tissue Sarcoma

NCT00900341
View directory record Official record
Conditions
Sarcoma
Interventions
DNA analysis, gene expression analysis, protein expression analysis, reverse transcriptase-polymerase chain reaction, western blotting, immunohistochemistry staining method, laboratory biomarker analysis
Genetic · Other
Lead sponsor
University of Arizona
Other
Eligibility
Not listed
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 21, 2014 · Synced Oct 16, 2026, 3:23 PM EDT
Not listed Phase 1 Interventional

Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas

NCT01107522
View directory record Official record
Conditions
Solid Tumors, Glioblastoma, Recurrent Malignant Gliomas
Interventions
CTO, CTO and Temodar®, CTO, Temodar®, Radiation therapy
Drug
Lead sponsor
Tactical Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
4
States / cities
New York, New York • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 16, 2026, 3:23 PM EDT
Recruiting Phase 2 Interventional

Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma

NCT06295159
View directory record Official record
Conditions
Melanoma Stage III, Melanoma Stage IV, Advanced Melanoma, Melanoma
Interventions
Nivolumab, Nivolumab + Relatlimab, Ipilimumab
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 16, 2026, 3:23 PM EDT
Recruiting Phase 2 Interventional

Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas

NCT07110246
View directory record Official record
Conditions
BRAF V600 Mutation, Low-grade Glioma, Low Grade Glioma of Brain, Recurrent Low Grade Glioma
Interventions
Dabrafenib, Trametinib, Magnetic Resonance Imaging (MRI), Specimen Collection, Optional Lumbar puncture
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
12 Months to 25 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
10
States / cities
Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 16, 2026, 3:23 PM EDT
Active, not recruiting Phase 1 Interventional

Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma

NCT01955460
View directory record Official record
Conditions
Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions
Aldesleukin, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, NGFR-transduced Autologous T Lymphocytes, TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes
Biological · Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 16, 2026, 3:23 PM EDT
Suspended Phase 1 Interventional

Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) for the Treatment of Patients With Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation

NCT05993611
View directory record Official record
Conditions
Chronic Graft Versus Host Disease, Hematologic and Lymphocytic Disorder, Steroid Refractory Graft Versus Host Disease
Interventions
Biopsy, Biospecimen Collection, Chimeric Antigen Receptor T-Cell Therapy, Computed Tomography, Echocardiography, Electronic Health Record Review, Leukapheresis, Lumbar Puncture, Magnetic Resonance Imaging, Quality-of-Life Assessment, Tafasitamab, X-Ray Imaging
Procedure · Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Oct 16, 2026, 3:23 PM EDT
Completed No phase listed Observational

IL-2 "SELECT" Tissue Collection Protocol in Patients With Advanced Melanoma

NCT01288963
View directory record Official record
Conditions
Malignant Melanoma
Interventions
IL-2
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 16, 2026, 3:23 PM EDT
Completed No phase listed Observational

Tissue and Plasma Biomarkers of Lymph Node Involvement in Cervical Cancer

NCT01546363
View directory record Official record
Conditions
Cervical Cancer
Interventions
Blood draw
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Oct 16, 2026, 3:23 PM EDT
Completed Phase 4 Interventional

MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I

NCT01501487
View directory record Official record
Conditions
Breast Cancer
Interventions
TAC chemotherapy, TC chemotherapy, Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy, TCH chemotherapy, T + trastuzumab followed by CEF + trastuzumab, Dose dense AC followed by T + trastuzumab, Dose dense AC followed by T + trastuzumab + pertuzumab, PTH followed by dose dense AC of FEC
Drug
Lead sponsor
Agendia
Industry
Eligibility
18 Years and older · Female only
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
9
States / cities
Mobile, Alabama • Clearwater, Florida • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2018 · Synced Oct 16, 2026, 3:23 PM EDT